Reported about 10 hours ago
Pfizer reported mixed first-quarter earnings, with adjusted earnings per share of $0.92 exceeding expectations while revenue of $13.7 billion fell short of the $14 billion consensus. CEO Albert Bourla emphasized the company's commitment to navigating a volatile market and announced increased cost-cutting measures to save $7.7 billion. Despite setbacks in its obesity treatment trials, Pfizer reiterated its 2025 revenue outlook of $61 to $64 billion.
Source: YAHOO